SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Interestingly enough, there may be merit in the suggestion that dapagliflozin, along with other SGLT2 inhibitors, may only exhibit ameliorative effects towards MASLD as a result of concomitant metabolic disorders.